OM336 in Autoimmune Cytopenias

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

An open-label, multicenter, ascending dose study, evaluating safety, tolerability, and PK/ADA of OM336 in autoimmune cytopenias.

Key Inclusion Criteria:

• Active autoimmune cytopenia
• Relapsed/refractory after ≥1 prior treatment
• Body weight ≥ 55 kg
• Willing to comply with and study requirements and procedures

Key Exclusion Criteria:

• Previous treatment with a BCMA-targeted therapy
• Clinically significant infection within 3 months of screening
• Major surgery or splenectomy within 3 months of screening or planned during the study
• Pregnant or breastfeeding